Human medicines European public assessment report (EPAR): Comirnaty, tozinameran,riltozinameran and tozinameran,famtozinameran and tozinameran,COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 virus infection, Date of authorisation: 21/12/2020, Revis

Human medicines European public assessment report (EPAR): Comirnaty, tozinameran,riltozinameran and tozinameran,famtozinameran and tozinameran,COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 virus infection, Date of authorisation: 21/12/2020, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Fycompa, perampanel, Epilepsies, Partial, Date of authorisation: 23/07/2012, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Fycompa, perampanel, Epilepsies, Partial, Date of authorisation: 23/07/2012, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Lupus Erythematosus, Systemic, Date of authorisation: 13/07/2011, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Lupus Erythematosus, Systemic, Date of authorisation: 13/07/2011, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endo

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms, Date of authorisation: 17/07/2015, Revision: 54, Status: Authorised

Human medicines European public assessment report (EPAR): Karvezide, irbesartan,hydrochlorothiazide, Hypertension, Date of authorisation: 16/10/1998, Revision: 47, Status: Authorised

Human medicines European public assessment report (EPAR): Karvezide, irbesartan,hydrochlorothiazide, Hypertension, Date of authorisation: 16/10/1998, Revision: 47, Status: Authorised

Human medicines European public assessment report (EPAR): Yescarta, axicabtagene ciloleucel, Lymphoma, Follicular;Lymphoma, Large B-Cell, Diffuse, Date of authorisation: 23/08/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Yescarta, axicabtagene ciloleucel, Lymphoma, Follicular;Lymphoma, Large B-Cell, Diffuse, Date of authorisation: 23/08/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Sprycel, dasatinib (anhydrous), Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 20/11/2006, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Sprycel, dasatinib (anhydrous), Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 20/11/2006, Revision: 41, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness